PharmaTher Says Focus Is Targeted Peptide Products, Not Competing With Telehealth Brands

PUBT · 3d ago
PharmaTher Says Focus Is Targeted Peptide Products, Not Competing With Telehealth Brands
  • PharmaTher CEO Fabio Chianelli said the company will focus on personalized peptide products rather than compete with telehealth brands selling commodity peptides.
  • Initial development targets colon-delivered KPV and BPC-157 using pharmaceutical 3D printing.
  • Chianelli sees opportunities in proprietary products and helping healthcare partners expand existing peptide portfolios.
  • KPV and BPC-157 are not FDA-approved; both qualify for conditional oral compounding under the new US pathway.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmather Holdings Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610291001NEWSFILECNPR____20261029_321580_1) on October 29, 2026, and is solely responsible for the information contained therein.